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Abstract
Neurologic disease is believed to be an unusual complication during the course of chronic lymphocytic leukemia.
Nevertheless, it has already been proven in autopsy series that the incidence of occult nervous system infiltration is
much higher than was previously expected. The advent of more potent drugs to treat this lymphoproliferative disorder
has brought a new hope for a possible cure in the future. However, an appropriate systemic treatment for central
nervous system infiltration of this disease is still lacking. Also, due to the potent immunosuppressive properties of the
agents used in the up-front treatment, for example, the purine nucleoside analogues, we have witnessed an increase
in the incidence of opportunistic infections, with progressive multifocal leukoencephalopathy being one of the most
serious. The goal of this review is to summarize the spectrum of neurologic derangements linked to chronic
lymphocytic leukemia and to raise clinicians’ awareness to recognize the possibility of such associations.
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Chronic lymphocytic leukemia (CLL), the most common leuke-
mia that occurs in adulthood, is considered an indolent malignancy
of the lymphoid tissue characterized by the proliferation and accu-
mulation of monoclonal, B-type, small, mature-appearing lympho-
cytes in the blood, bone marrow, and lymphoid tissues. The median
age of patients at diagnosis is 65 years, with only 10% to 15% 50
ears of age. Men are more affected than women. The course of the
isease is variable. That is, most patients with CLL have a normal life
pan, whereas a subgroup with a more aggressive disease may have a
horter survival after diagnosis.1 CLL frequently is accompanied by a
multitude of immune abnormalities. Defects in both cell-mediated
(quantitative and functional B lymphocyte, T cell, natural killer
(NK) cells, neutrophils, and the monocyte and/or macrophage ab-
normalities) and humoral-mediated immunity (low gamma globulin
levels) together are responsible for the many disease-specific compli-
cations of CLL.2,3 The central nervous system (CNS) and peripheral
nervous system (PNS) are potential targets for CLL-related compli-
cations, which are at serious risk of being neglected because it is
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Clinical Lymphoma, Myeloma & Leukemia June 2012generally assumed that CLL neurologic complication rates are low.4
In addition to this belief, clinicians may not be sufficiently aware and
prepared to establish an association between the neurologic symp-
toms and the CLL disease itself, and lose time in search of other
etiologies and risk letting the disease reach an irreversible situation.
This review discusses, and also constitutes a reminder of, the
vast spectrum of CLL neurologic complications that include not
just direct brain, meninges, and root plexus infiltration by the
neoplastic cells but also opportunistic infections and secondary
brain malignancies due to impaired immunity, CLL therapy-re-
lated neurotoxicity, and other lesser well-known but potential
neurologic issues, such as metabolic encephalopathies and para-
neoplastic neurologic syndromes (Table 1).
Methods
In this narrative literature review, a search strategy that incorpo-
rated PubMed-Medline search engines and used the keywords
chronic lymphocytic leukemia/leukaemia, small lymphocytic lym-
phoma, Richter syndrome, central nervous system, meningitis, en-
cephalitis, cerebrospinal fluid, brain tumor, hypophysis/hypothala-
mus, optic nerve, retina, infection, hemorrhage/haemorrhage, drugs,
treatment, chlorambucil, fludarabine, rituximab, neurotoxicity, pro-
gressivemultifocal leukoencephalopathy, peripheral nervous system, au-
toimmune neuropathies, vitamin, hypercalcemia, hyponatremia, para-
neoplastic neurological syndrome invarious combinationswasused, and
articleswere evaluatedonan individual basis.The search strategywasnot
limited by year of publication, andno language restrictionswere applied.
The search included all research document types, including journal ar-
2152-2650/$ - see frontmatter © 2012 Elsevier Inc. All rights reserved.
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ports, reviews), abstracts, and any pertinent document found on the
Internet.A reviewof the reference sectionof all articles retrieved fromthe
PubMed-Medline database was done to search for any additional rele-
vant articles that could have been overlooked by the electronic search.
The articles were selected if they met the criteria of direct or indirect
neurologic involvement by CLL and/or small lymphocytic lymphoma
and Richter syndrome (RS) transformation.
CLL and CNS Disease
Knowing that CLL is the most common lymphoproliferative dis-
order in theWestern world, with an annual estimated frequency of 3
per 100,000 and that 100 cases of CNS involvement had been
eported antemortem in the past 35 years, one at first may be led to
elieve that CNS invasion is an uncommon event. (Tables 2, 3).5-71
This is not entirely true for several reasons. First, CNS involvement
by CLL is often underdiagnosed and underreported because the neu-
rologic manifestations are nonspecific, and the clinicians may not be
sufficiently aware of the possible association between these 2 entities.
Second, asymptomatic CNS disease is more prevalent. The postmor-
tem studies confirm this observation: 1 autopsy series detected CNS
infiltration in 10 of 14 advanced stage CLL cases, although none of
these patients had any neurologic symptoms.68 In another series of
100 consecutive patients, 16 of whom had CLL, it was found that up
to 50% had the silent CNS disease.69 In a third autopsy series, the
reported brain or spinal cord tumor CLL involvement ranged
from 17% to 71% of the cases.70 Also, in a fourth study, which
included 109 patients with CLL diagnosed between 1958 and
1982, the percentages of CNS involvement of the brain, dura
mater, and leptomeningeal were 7%, 21%, and 8%, respec-
tively.71 These findings suggest that CLL infiltration in the CNS
Table 1 Overview of the Spectrum of Neurologic
Complication in Chronic Lymphocytic Leukemia
Central Nervous System Etiology
Parenchymal
Leukemic
Tumor
Infectious
Iatrogenic
Hemorrhagic
Metabolic
Meningeal
Leukemic
Infectious
Hemorrhagic
Epidural Leukemic
Optic Nerve
Leukemic
Infectious
Iatrogenic
Peripheral Nervous System
Leukemic
Autoimmune
Iatrogenichappens at a much higher rate than was expected. Third, clinicalovert neurologic manifestations generally occur in more advanced
disease stages or during transformation to RS, although many
cases also are diagnosed in the early Rai 0-I stage. There are even
situations in which the neurologic symptoms represent the inau-
gural manifestation of CLL, creating great difficulties to establish,
at first, a causal relationship between the hematologic malignancy
and the neurologic symptoms. Taken altogether, CNS involve-
ment by CLL is not as rare as it seems to be.
CLL and Meningoencephalitis
Considering only brain parenchyma and/or meningeal infiltration
and spinal cord compression by CLL, 67 cases have been described so
far,5-71 a number that is much higher than the previous re-
ports.34,56,64 The retina and optic nerve, which also belong to the
pectrum of CNS involvement by CLL, will be discussed in a sepa-
ate section, as well as RS of the CNS. In CLL meningoencephalitis,
en are affected twice as much as women, and the median age at
iagnosis is 64 years. CLL presentation as small lymphocytic lym-
homa (SLL) was observed in 4 patients.38,46,59,63 The distribution
according to the Rai staging system was the following: early-stage
disease Rai 0-I (n  30), intermediate stage Rai II (n  18), and
dvanced stage Rai III-IV (n 19). CNS plus systemic disease is the
ule, but isolate CNS involvement alone can sometimes oc-
ur.7,32,57,61 Time fromCLL diagnosis until CNS documentation of
isease ranged from 0 days to 15 years (median, 4.5 years). It is
urious to note that 12 cases of brain and/or meningeal infiltration
resented as the initial manifestation of diagnosis of CLL (including
dura and/or brain SLL, and 3 pituitary and/or hypothalamus
LL).19,37-40,45,48-50,57,61,63
There appears to be no correlation between CNS involvement and
disease stage in CLL, duration of CLL, sex, age, immunologic phe-
notype, or peripheral leukocyte count.70 However, it was suggested
hat progression to RS seems to predispose to the meningeal inva-
ion.42 The spectrum of neurologic manifestations is heterogeneous,
ncluding headache, cranial nerve palsies (the optic nerve is affected
n about a fourth of cases), cerebellar signs, paresis (mainly lower
imbs), and visual abnormalities. Paraplegia due to complete cord
ompression was documented in only 4 instances and carries a very
ad prognosis,7,16,20,36 except in 1 patient in whom prompt decom-
pression surgery plus irradiation and systemic chemotherapy were
life saving.36 Current neuroimaging techniques have low sensitivity
for CLL infiltration49,52,64 because negative or nonspecific results
brain SLL can even be confused with meningioma)63 are the rule,
nd only 4 cases showed a brain mass on computed tomography
nd/or magnetic resonance without infiltration in the cerebrospinal
uid (CSF).50,61,62,65
The definitive diagnosis usually is made by CSF analysis. Cyto-
morphology coupled with immunophenotyping raise the probability
of detecting themonoclonal B cells.49,56 In 2 instances, the use of the
polymerase chain reaction (PCR) method that selectively amplified
the highly variable and clone-specific CDR3 region of the locus en-
coding the immunoglobulin heavy chain in DNA obtained from
both CSF and peripheral blood cells allowed to the establishment of
the suspected diagnosis when both cytology and flow cytometry
failed to clarify the clinical suspicion of leptomeningeal disease.35,40Notwithstanding, there are cases in which CSF was negative for the
Clinical Lymphoma, Myeloma & Leukemia June 2012 165
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166Table 2 Clinical Characteristics, Type of Neurologic Involvement, and Symptoms of the Patients With Documented CNS
Involvement by CLL and/or SLL
Study Sex/Age Disease Rai Stage Sys D CNS Site Time to CNS Disease Clinical Manifestations
Amiel and Droz,5 1976 M/69 CLL 0 Y LM NA Headache, ataxia, deafness, cranialnerve palsies
Nemoto et al,6 1978 M/33 CLL II N P NA Visual loss
Getaz and Miller,7 1979 F/65 CLL IV Y SC NA Leg weakness
Liepman andVotaw,8 1981
F/68 CLL IV Y LM NA Cranial nerve palsies
M/58 CLL IV Y LM 36 mo Lethargy
Korsager et al,9 1982
M/64 CLL II Y LM NA Dementia
M/58 CLL II Y LM NA Dementia
Solal-Celigny et al,10 1983 NA CLL NA NA LM NA NA
Steinberg et al,11 1985 M/38 CLL III Y LM NA Lethargy, proptosis
Singh and Thompson,12 1986 M/56 CLL II Y LM NA Ataxia, cranial nerve palsy
Boogerd and Vroom,13 1986 M/74 CLL 0 Y LM NA Gait disturbance, tinnitus
Cash et al,14 1987
F/59 CLL 0 Y LM NA Visual loss, legs weakness, sensoryimpairment
M/57 CLL 0 Y LM NA Headache, gait disturbance
Stagg and Gumbart,15 1987 F/66 CLL III Y LM NA Headache, SIADH
Lustman et al,16 1988 NA CLL I Y SC NA Paraplegia, legs paresthesias
Currie et al,18 1988
M/76 CLL III Y ON NA Visual loss
F/45 CLL III Y ON NA Visual loss
M/67 CLL IV Y ON NA Visual loss
Garofalo et al,19 1989 F/72 CLL 0 Y H At diagnosis Headache, lethargy, confusion, leg/back pain
Michalevicz et al,20 1989 F/78 CLL I Y SC 72 mo Paraplegia
Grisold et al,23 1990 F/63 CLL IV Y LM 3 mo Gait disturbance, legs weakness,sensory neuropathy
Patton et al,24 1992 NA CLL NA Y B LM NA NA
Fain et al,25 1992 F/57 CLL NA NA P NA Visual loss
Ruiz et al,26 1992 M/79 CLL IV Y LM 156 mo Visual loss
Rubin and Harris,27 1993 M/73 CLL 0 NA LM NA Confusion, visual loss, facial pain
Pohar et al,29 1993 M/63 CLL NA NA B NA Gait disturbance, legs weakness
Paolini et al,31 1995 NA CLL II Y LM NA Headache
Cramer et al,70 1996 F/62 CLL 0 Y LM NA Gait disturbance, legs weakness
Morrison et al,32 1998 M/61 CLL IV N LM 4 wk Ataxia, vertigo, occipital headaches
Hagberg et al,33 1997
NA CLL NA Y LM NA SIADH
NA CLL NA Y LM NA SIADH
Miller et al,34 1997 M/44 CLL 0 Y LM NA Visual loss, paresthesias
Garicochea et al,35 1997 NA CLL NA NA LM NA NA
Majumdar,36 1998 M/66 CLL I Y SC 22 mo Paraplegia, legs paresthesias
Perez et al,37 1998 M/65 CLL 0 Y LM At diagnosis Headache, confusion, diplopia
Poplawska-Szczyglowska et al,38
1999 M/68 CLL/SLL II Y B At diagnosis Hemiparesis, aphasia
Elliot et al,39 1999 M/52 CLL 0 Y LM At diagnosis Left leg paresis, visual loss, backpain
Vogt-Schaden et al,40 1999 M/54 CLL I-II Y LM 60 mo Diplopia, facial and hypoglossal nervepalsy, left leg paresis
Marmont,42 2000 M/70 CLL 0 Y LM 144 mo Confusion, legs pain(continued on next page)
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Rodrigo Lopes da Silvamalignant cells. Under these circumstances, if a mass is readily acces-
sible by biopsy, then histopathologic analysis of the specimen con-
firms its precise neoplastic nature. In this regard, 11 CLL cases (3
pituitary disease, 3 SLL, and the remaining dural involvement by
CLL) were documented by brain biopsy.6,25,29,44,46,48,50,58,61-63
The interpretation of CSF analysis in patients with CLL is not always
Table 2 (continued)
Study Sex/Age Disease Rai Stage S
Wang et al,43 2000 M/81 CLL IV
Rye et al,44 2001 M/61 CLL IV
Akintola-Ogunremi et al,45 2002 F/89 CLL 0
Estevez et al,46 2002 F/70 CLL/SLL II
Brick et al,47 2002 M/77 CLL 0-I
Kaiser,48 2003 M/53 CLL II
Remkova et al,49 2003 M/78 CLL 0
Nimubona et al,50 2004 F/43 CLL 0
Watanabe et al,52 2005 F/70 CLL 0-II
Knop et al,53 2005
M/83 CLL II
F/68 CLL I
F/74 CLL II
M/42 CLL II
F/53 CLL III
Schmidt-Hieber et al,54 2005 M/71 CLL I
Lange et al,56 2007 F/61 CLL II
Kalac et al,57 2007 M/62 CLL 0-I
Giordano et al,59 2007 NA CLL/SLL NA
Kiewe et al,61 2007 M/42 CLL I
Kakimoto et al, 2010 M/58 CLL III
Kelly et al,63 2008 M/74 CLL/SLL I
Hanse et al,64 2008
M/74 CLL I
M/57 CLL I
M/68 CLL IV
M/71 CLL III
M/69 CLL NA
M/65 CLL I
Calvo-Villas et al,67 2010
M/52 LM CLL I
M/44 CLL IV
M/81 CLL 0
F/64 CLL IV
Abbreviations: B  brain; CLL  chronic lymphocytic leukemia; CNS  central nervous syste
P pituitary; SC spinal cord; SIADH syndrome of inappropriate antidiuretic hormone hypstraightforward. First, due to derangements of humoral and cellularimmune functions, CNS opportunistic infections may be associated
with false-positive cytologies. Viral meningitis is classically described
as being associated with a lymphocytic CSF, but it must be remem-
bered that polymorphonuclears (PMN)may predominate, especially
early in the illness. Reactive nonclonal lymphocytosis is also seen in
fungal infections and in 10% of bacterial meningitis, although a
CNS Site Time to CNS Disease Clinical Manifestations
LM 29 mo NA
P At diagnosis SIADH
LM At diagnosis Altered mental status
Dura B NA Ataxia, deafness, vision loss,hyperesthesia of the scalp
LM 48 mo Headache, diplopia, cranial nervepalsy
B At diagnosis Focal jacksonian seizures
LM At diagnosis Headache, lethargy, loss of vision
P At diagnosis Panhypopituitarism
LM 12 mo Headache, ophthalmalgia, tinnitus,confusion
LM 32 mo Diplopia
LM 94 mo Facial nerve palsy, left leg paresis
LM 4 mo Hyperesthesia, paresthesia
LM 54 mo Asymptomatic
LM 55 mo Paresthesia, neuropathic pain
LM 6 mo Paraparesis
LM 36 mo Lower limbs weakness, left legparesis
LM At diagnosis Right hemiparesis, lethargy,hallucinations
B NA NA
Dura At diagnosis Headache, diplopia, facial nerve palsy
B LM 132 mo Memory loss, progressive blinding
Dura B At diagnosis Left face and arm seizure andparesthesias
LM 54 mo Headache
LM 1 mo Facial nerve palsy, L3 syndrome
LM 75 mo Confusion, headache
LM 53 mo Diplopia, trigeminus nerve palsy,vertigo
LM 108 mo Diplopia, deafness
LM 36 mo Left leg paresis, left facehypoesthesia
LM 60 mo Headache, lethargy
LM 24 mo Headache, face dysesthesia, visionloss
LM 24 mo Headache, lethargy, confusion
LM 12 mo Headache, diplopia
hypothalamus; LM  leptomeninges; NA  not available or not stated; ON  optic nerve;
tion; SLL small lymphocytic lymphoma; Sys D systemic disease.ys D
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
N
NA
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Ypredominance of PMNs may be present in the early stages of these
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168Table 3 Diagnostic Procedures, Treatment, Response, and Outcome of the Patients With Documented Central Nervous System
Involvement by Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
Study Neuroimaging CSF Histology Treatment Response Outcome
Amiel and Droz,5 1976 NA NA No IT (MTX) RT CR Alive
Nemoto et al,6 1978 NA NA Yes None NR Dead
Getaz and Miller,7 1979 NA NA No IT (MTX) NR Dead
Liepman and Votaw,8 1981
NA Positive No IT (MTX) CR Dead
NA Positive No IT (MRX) RT CR Alive
Korsager et al,9 1982 NA Positive No IT (MRX) RT CR Alive
NA Positive No None NR Dead
Solal-Celigny et al,10 1983 NA NA No IT (MTX) CR NA
Steinberg et al,11 1985 NA Positive No IT (MTX) RT CR Alive
Singh and Thompson,12 1986 NA Positive No IT (MTX) RT CR Alive
Boogerd and Vroom,13 1986 NA Positive No None NR Dead
Cash et al,14 1987 NA Positive No IT (MTX araC) RT CR Alive
NA Positive No IT (MTX araC) RT CR Alive
Stagg and Gumbart,15 1987 NA Positive No IT (MTX) CR Alive
Lustman et al,16 1988 NA NA No NA NA NA
Currie et al,18 1988
NA NA No RT PR NA
NA NA No RT PR NA
NA NA No RT PR NA
Garofalo et al,19 1989 Positive Positive No Ventricular shunt NR Dead
Michalevicz et al,20 1989 NA Negative No DXM NR Dead
Grisold et al,23 1990 NA NA No None NR Dead
Patton et al,24 1992 NA NA No NA NA NA
Fain et al,25 1992 Positive Positive Yes Surgery CR Alive
Ruiz et al,26 1992 NA Positive No NA NA NA
Rubin and Harris,27 1993 NA NA No None NR Dead
Pohar et al,29 1993 Positive NA Yes RT PR Alive
Paolini et al,31 1995 NA NA No I.V. (Flu) CR Alive
Cramer et al,70 1996 NA Positive No IT (MTX araC) RT CR Alive
Morrison et al,32 1998 NA Positive No IT (MTX) RT CR Alive
Hagberg et al,33 1997
NA NA No NA NA NA
NA NA No NA NA NA
Miller et al,34 1997 NA Positive No IT (MTX araC) RT CR Alive
Garicochea et al,35 1997 NA Only PCR No NA NA NA
Majumdar,36 1998 NA Negative Yes Surgery RT COP CR Dead after 42mo
Perez et al,37 1998 Normal Positive No IT (MTX) RT PR Dead
Poplawska-Szczglowska et al,38
1999 Positive Positive No IT (MTX) PR Dead after 6 mo
Elliot et al,39 1999 Positive Positive No I.V. (Flu) CR Alive
Vogt-Schaden et al,40 1999 Normal Only PCR No None NR Dead after weeks
Marmont,42 2000 Normal Positive No IT (MTX) RT CR Alive
Wang et al,43 2000 NA Positive No IT Chemo RT CR Dead
Rye et al,44 2001 Normal NA Yes I.V. (Flu) PR Dead(continued on next page)
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Rodrigo Lopes da Silvainfections. The cornerstone for the diagnosis of CLL leukemic infil-
tration of the CNS is accomplished by proving the monoclonality of
the cytologically abnormal malignant lymphocytes in the CSF. Even
so, the demonstration of monoclonal B cells in CSF does not allow
affirmation with certainty of the presence of tumoral CNS involve-
ment in such infectious cases because patients with CLL who have
high circulating malignant B cells may show infiltration of clonal
lymphocytes in sites of CNS inflammation as a part of a reactive
process.72 Second, traumatic introduction ofmonoclonal B cells into
he CSF during lumbar puncture occurs 20% of the time and would
esult in an artificial increase in white blood cells from 1 for every 500
o 1000 red blood cells in the CSF and hence be responsible for the
ontamination of the CSF with malignant B cells. To avoid misin-
Table 3 (continued)
Study Neuroimaging CSF Histolo
Akintola-Ogunremi etal,45 2002 Normal Positive No
Estevez et al,46 2002 NA NA Yes
Brick et al,47 2002 NA Positive No
Kaiser,48 2003 NA Negative Yes
Remkova et al,49 2003 Normal Positive No
Nimubona et al,50 2004 Positive Negative Yes
Watanabe et al,52 2005 Normal Positive No
Knop et al,53 2005
Normal Positive No
Normal Positive No
Normal Positive No
Normal Positive No
Positive Positive No
Schmidt-Hieber et al,54 2005 Normal Positive No
Lange et al,56 2007 Positive Positive No
Kalac et al,57 2007 Normal Positive No
Giordano et al,59 2007 NA NA No
Kiewe et al,61 2007 Positive Negative Yes
Kakimoto et al, 2010 Positive Negative Yes
Kelly et al,63 2008 Positive NA Yes
Hanse et al,64 2008
Normal Positive No
Positive Positive No
Normal Positive No
Normal Positive No
NA Positive No
Positive Negative No
Calvo-Villas et al,67 2010
NA Positive No
NA Positive No
NA Positive No
NA Positive No
Abbreviations: araC  cytarabine; CHOP  cyclophosphamide/doxorubicin/vincristine (Oncov
CR  complete response; DXM  dexamethasone; Flu  fludarabine; IT  intrathecal; I
CR polymerase chain reaction; PR partial response; R rituximab; RT radiotherapy.erpretation with neoplastic infiltration, subsequent lumbar punc-ures can be performed to ascertain if the presence of malignant cells
s fleeting or is related to a true neoplastic CNS infiltration. Third,
esults of 1 study suggested that, in patients with lymphoid neo-
lasms such as CLL, the presence of a neoplastic B-cell clone popu-
ation in the CSF is not diagnostic of clinically significant involve-
ent of the CNS but may be caused by the trafficking of
ymphocytes, although a longer follow-up of the patients is needed to
onfirm this observation.72
An appropriate and optimal systemic treatment for CNS involve-
ment of CLL still remains to be established. However, management
of CNS symptoms with single or triple intrathecal chemotherapy
given twice a week for 4 weeks and then once weekly for a total
maximum of 12 administrations, followed or not by radiotherapy, is
Treatment Response Outcome
None NR Dead
NA NA NA
IT (MTX araC) CR Alive
RT CR Alive after 1 y
IT (MTX DXM) CR Alive
Surgery CR Alive
IT (MTX DXM) R CR Alive
None NR Dead after 1 mo
RT PR Dead after 5 mo
IT (MTX) CR Dead after 6 mo
I.V. (Flu) CR Alive after 20 mo
IT (MTX araC DXM) PR Dead after 3 mo
IT (MTX araC DXM) NR Dead
IT (MTX liposomal araC) COP PR Dead after 6 mo
IT (DXM) CLB CR Alive
NA NA NA
Surgery DXM RT CR Alive
I.V. (MTX Flu) RT NR Dead after 6 mo
RT NA NA
IT (MTX araC) CLB CR Alive
IT (MTX araC) RT CLB CR Alive
IT (MTX) CHOP CR Alive
IT (MTX araC)RT PR Dead after 5 mo
T (MTX araC DXM) I.V. (MTX araC) CR Alive
IT (Mtx araC DXM) I.V. (MTX araC) CR Alive
IT (liposomal araC) RT CR Alive
IT (liposomal araC) CR Dead after 12mo
IT (liposomal araC) CR Dead after 3 mo
IT (liposomal araC) CR Alive
nisolone; COP  cyclophosphamide/vincristine (Oncovin)/prednisolone; CLB  chlorambucil;
intravenous; MTX  methotrexate; NA  not available or not stated; NR  no response;gy
I
in)/predusually the rule. The body’s blood-brain barrier does not allowmany
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170chemotherapy drugs given systemically to get to the CSF. Water-
soluble ionized molecules given intravenously as single injections do
not penetrate the blood brain-barrier to any great degree. The prin-
cipal drugs used to treat CNS disease in CLL are methotrexate
(MTX), cytarabine, steroids, and fludarabine. MTX is an antimetab-
olite drug that inhibits dihydrofolate reductase. It is poorly trans-
ported across the blood-brain barrier, and therapeutic concentration
in CNS only occurs with high-dose therapy or by an intrathecal
administration in which it presents a highly uniform distribution in
the intrathecal space, which produces the most consistent levels of
CSF compared with other routes of administration.73 Cytarabine, a
yrimidine nucleoside that inhibits the DNA polymerase, has a poor
nd unpredictable absorption after oral administration. Cytarabine is
dministered intravenously or intrathecally. Anyhow, data regarding
ts capacity to cross the blood-brain barrier are limited, and, when
iven intrathecally, most of the dose diffuses into the systemic circu-
ation.74 Its liposomal formulation offers a better form to deliver this
rug into the CNS in a sustained form. The steroid dexamethasone
as poor brain penetration.75 Nonetheless, given intrathecally, all of
the prodrug is converted into its active form and attains steady levels
in the CSF.76 Fludarabine, a purine nucleoside, has been shown to
iffuse into the CNS by a specific transport mechanism in animal
odels.77 Because the arachnoid space and nerve roots are not pro-
tected by the blood-brain barrier, a good control of leptomeningeal
and cranial nerves disease could be achieved in patients withCLL and
of leptomeningeal disease with this drug, as has been suggested by a
study.53
From the available data in the medical literature, dura or paren-
chymal infiltration and leptomeningeal invasion occurred in 12 and
55 patients, respectively. Dura and parenchymal disease therapy was
based on radiotherapy (n  3), surgery (n  3), radiotherapy plus
urgery (n 1), chemotherapy (n 2), or none or no data available
(n 3), and the responses were varied. Patients with leptomeningeal
disease (n  55) were treated with radiotherapy alone (n  1),
intrathecal MTX plus systemic chemotherapy (n  7), intrathecal
MTX plus radiotherapy (n 6), intrathecalMTX, and cytarabine or
steroids with or without radiotherapy, and systemic chemotherapy
(n 16), intrathecal liposomal cytarabine with or without radiother-
apy and systemic chemotherapy (n 5), intravenous fludarabine as
monotherapy or combined with MTX plus radiotherapy (n  4),
systemic chemotherapy with or without radiotherapy (n  3), and
no therapy or unknown (n  13).
A higher number of clinical neurologic and laboratory complete
responses as well as better outcomes were observed among patients
treated with an intrathecal combination of chemotherapy with or
without radiotherapy (n 22), with a complete response in 19 of 22
patients, 2 of 22 with partial responses, and 1 of 22 without response,
whereas fewer good response rates and outcomes were associated
with radiotherapy or intrathecal MTX used alone.
Systemic fludarabine has been used in 4 instances to treat the
leptomeningeal invasion, and, in 3 of 4 patients, complete neurologic
disease remission was observed.39,44,58,63 Intrathecal liposomal
ytarabine given as monotherapy appears to be a good approach
ecause it showed promising results. In a retrospective study that
nvolved 7 patients, of whom 4 had leptomeningeal invaded by CLL,
ll attained complete clinical and laboratory responses.67 Although t
Clinical Lymphoma, Myeloma & Leukemia June 2012udarabine and liposomal cytarabine can be favorable therapeutic
ptions for CNS invasion, further larger series studies are necessary
o validate their efficacy. Prognosis could be improved by a timely
iagnosis and prompt and aggressive therapy, which allows induc-
ion of durable complete clinical and laboratory resolution of neuro-
ogic abnormalities. Nevertheless, prognostic factors for the risk of
NS involvement remain to be determined yet and are urgently
equired to allow a better management of these situations.
CLL and Hypophysis and/or Hypothalamus Disease
In very rare instances, CLL invasion of the sella turcica is observed,
and a diagnosis is made as a consequence of symptomatic disease.
The first reported case occurred in a young patient with relapsedCLL
manifested as visual disturbances due to an isolate sellar mass without
systemic disease, which simulated a pituitary (hypophysis) tumor.
The final diagnosis was only obtained after an autopsy.6 In another
patient, direct involvement of the pituitary gland resulted in adrenal
insufficiency and gonadotrophin deficiency. Moreover, the exten-
sion of the lesion upward into the suprasellar region culminated in
compression of the optic chiasm and bitemporal hemianopsia en-
sued.25 When no traumatic injury is present, this clinical finding is
pathognomonic for a pituitary tumor. In an extreme case, a pituitary
tumor consists of CLL cells presented as panhypopituitarism (hyper-
thyroidism, hyperprolactinemia, hypocortisolemia). A complete re-
sponse was attained after surgery, and the patient was receiving hor-
monal supplementation.50 Hyponatremia, of 115 mmol/L, due to
n inappropriate antidiuretic hormone secretion syndrome is an-
ther rare complication of CLL and may arise as a secondary com-
lication of CNS infections, leptomeningeal invasion, and, very un-
ommonly, direct pituitary involvement. In this specific case,
euroimaging was perfectly nonspecific and definitive diagnosis was
ade at postmortem.44
Despite the apparent rarity of pituitary invasion, autopsy studies
revealed that, in fact, the pituitary is one of the most often involved
sites in the CNS by CLL.71 Hypothalamic invasion by CLL is also
possible and was diagnosed in only 1 instance in a patient with a
clinical picture of intracranial hypertension, with headache and con-
fusion due to obstruction of the foramina of Monro and who re-
quired urgent surgical decompression without success.19
CLL and RS of the Brain
RS is defined as the transformation of a low-grade CLL and/or
small lymphocytic lymphoma (SLL) to a more aggressive high-grade
malignant form, usually diffuse, large B-cell, non-Hodgkin lym-
phoma and, more unusually, Hodgkin lymphoma. RS is not truly a
second malignancy because the CLL clone appears to be involved.
However, much debate exists about whether the transformation rep-
resents a common origin, with the emergence of a more malignant
clone of CLL cells or if a distinct independent clonal evolution is the
case.78 The incidence of RS varies between 3% and 10.6% of pa-
tients with CLL, and its involvement of the CNS is extremely rare,
with only 17 cases described so far (16 non-Hodgkin lymphoma and
1 Hodgkin lymphoma) since the first report in 1988.
(Tables 4, 5).17,21,22,28,30,41,51,55,58,60,65-67,79 In order of frequency,
he brain parenchyma is the preferred affected site and has a dismal
rognosis even after treatment, followed by the leptomeninges and
he dura mater. Isolated extranodal (brain) involvement without sys-
dRodrigo Lopes da SilvaTable 4 Clinical Characteristics, Type of Neurologic Involvement and Symptoms of the Patients With Documented CNS
Involvement by Richter Syndrome
Study Sex/Age Disease Rai Stage Sys D CNS Site Time to CNSInvolvement, mo Clinical Manifestations
Lane et al,17 1988 M/45 CLL/RS NA Yes B NA NA
O’Neill et al,21 1989
NA CLL/RS NA No B NA NA
NA CLL/RS NA No B NA NA
Bayliss et al,22 1990 NA CLL/RS NA NA B NA NA
Robertson et al,28 1993 NA CLL/RS NA NA B NA NA
Mahé et al,30 1994
NA CLL/RS NA No B NA NA
NA CLL/RS NA No B NA NA
Agard et al,41 1999 NA CLL/RS NA Yes B LM NA Cranial nerve palsies
Robak et al,51 2004 F/60 CLL/RS NA Yes B NA Stroke
Resende et al,55 2005 M/74 CLL/RS I Yes B 72 Gait disturbance, confusion
Ghofrani et al,58 2007 M/64 CLL/RS II Yes Dural B 60 Headache, vision loss
Bagic et al,60 2007 F/58 CLL/RS NA No B 36 Left leg paresis
Denier et al,65 2009 M/80 CLL/RS II Yes LM 24 Confusion, diplopia, right legparesis; VI nerve palsy
Almhanna et al,66 2009
M/65 CLL/RS Yes B 96 NA
F/68 CLL/RS IV Yes LM 36 Trigeminus nerve palsy
M/79 CLL/RS IV Yes LM 60 Gait disturbance, facial nerve palsy,lower limbs weakness
F/78 CLL/RS IV Yes LM 24 HeadacheAbbreviations: B brain; CLL chronic lymphocytic leukemia; CNS central nervous system; LM leptomeninges; NA not available or not stated; RS Richter syndrome; Sys D systemic
isease.Table 5 Diagnostic Procedures, Treatment, Response, and Outcome of the Patients With Documented Central Nervous System
Involvement by Richter Syndrome
Study Neuroimaging CSF Histology Treatment Response Outcome
Lane et al,17 1988 NA Positive No NA NA NA
O’Neill et al,21 1989
NA NA No NA NA NA
NA NA No NA NA NA
Bayliss et al,22 1990 NA NA No NA NA NA
Robertson et al,28 1993 NA NA No NA NA NA
Mahé et al,30 1994
NA NA No NA NA NA
NA NA No NA NA NA
Agard et al,41 1999 Normal Positive No NA NA Alive
Robak et al,51 2004 Positive Negative Yes RT CR
Resende et al,55 2005 Positive Negative Yes IT (MTX araC DXM) RT CLB CR Dead after 5 mo
Ghofrani et al,58 2007 Positive NA Yes R-CHOP RT PR Dead after 3 mo
Bagic et al,60 2007 Normal NA Yes RT R NA NA
Denier et al,65 2009 Normal Negative No IT (MTX araC DXM) NR Dead
Almhanna et al,66 2009
NA Positive No NA NA NA
NA Positive No IT (liposomal araC) CR Dead after 1 mo
NA Positive No IT (MTX araC DXM liposomal araC) CR Dead after 1 mo
NA Positive No IT (MTX araC DXM liposomal araC) CR Alive
Abbreviations: araC  cytarabine; CHOP  cyclophosphamide/doxorubicin/vincristine (Oncovin)/prednisolone; CLB  chlorambucil; CR  complete response; CSF  cerebrospinal fluid; DXM-
dexamethasone; I.V. intravenous; IT intrathecal; MTX methotrexate; NA not available or not stated; NR no response; PR partial response; R-CHOP rituximab/cyclophosphamide/
doxorubicin/vincristine (Oncovin)/prednisolone; RT radiotherapy.
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172temic disease occurs in up to 45% of cases.55 Neurologic manifesta-
ions appear abruptly and range from confusional states, gait disor-
ers, monoparesis, and cranial nerve palsies to signs of intracranial
ypertension (headache, papilledema). In 1 report, stroke was the
naugural manifestation of a cerebral RS.51 Neuroimaging reveals a
hypodense area of the brain with or without contrast enhancement or
can be nonspecific if the meninges are the predominantly affected
site.30,41 In the latter scenario, immunophenotyping of CSF is help-
ul to the final diagnosis. It should be emphasized that CNS (brain
arenchyma) RS shares similar neuroimaging characteristics with
ultiform glioblastoma.55 However, brain biopsy followed by im-
unohistochemical studies yield the definitive diagnosis. Treatment
onsists of radiotherapy and intrathecal chemotherapy (plus immu-
ochemotherapy if systemic disease is present). In 2 patients, surgery
as performed: 1 for a Hodgkin variant of cerebral RS and another
or a relapsed brain RS in which a frontal lobectomy was done with-
ut incident. Both patients eventually died.55,58 Survival has been
dismal because the patient’s disease usually is advanced at the time of
presentation and have a poor response. Notwithstanding, therapy
can improve the symptoms and the quality of life. Recently, in a
retrospective study, 3 patients with RS of the CNS treated with
intrathecal liposomal cytarabine achieved a sustained complete re-
sponse, which included resolution of the neurologic symptoms and
clearance of the CSF malignant cells, without relevant drug adverse
effects.67 Although the preliminary results are promising, prospec-
ive randomized studies are needed to confirm this.
CLL and Ophthalmology Disease (Retinopathy and
Optic Neuropathy)
Ophthalmic disease in CLL is very uncommon. In 1 prospective
study, it was found that CLL-associated ocular complications in-
cluded bilateral posterior subcapsular cataract after radiotherapy,
unilateral conjunctival vascular anomalies, and unilateral acute reti-
nal necrosis. Those manifestations were not related to the CLL
stage.80 As an extension of the CNS, the retina can be affected by
CLL in different ways. Retinal detachments accompanied by ocular
pain or decreased vision may be the first sign of the underlying CLL
or even RS and are a consequence of infection or, more rarely, direct
tumor infiltration or hyperviscosity.81-85 Peripheral retinal microa-
eurysm due to prolonged leukocytosis can induce peripheral capil-
ary dropout, vascular stagnation, microaneurysm formation, and
eripheral proliferative retinopathy.86 Cancer-associated retinopa-
hy, although not considered a paraneoplastic neurologic syndrome
nymore, was described in 1 instance in a patient with CLL in whom
he presence of serum antibodies to retinal enolase were detected.87
Infectious necrotizing retinopathy with ensuing optic atrophy or to-
tal retinal detachment and proliferative vitreoretinopathy is another
possible complication of CLL-associated retinal disease. CLL and a
CLL-therapy–induced state of immunosuppression render the pa-
tients prone to opportunistic infections. The simultaneous occur-
rence of infection with multiple agents can happen. Triple viral ret-
initis (herpes simplex, varicella zoster, and cytomegalovirus) and
retinitis due to toxoplasmosis with concomitant ocular reactivation
of varicella-zoster virus and cytomegalovirus were reported under
those circumstances. Specific antimicrobial treatment may resolve
retinal necrosis, but visual recovery remains poor due to optic nerve
Clinical Lymphoma, Myeloma & Leukemia June 2012atrophy.88-91 However, results of a report suggest that adding intra-
venous gamma globulinmay promote humoral immunity and can be
beneficial for a rapid visual improvement.92 Iatrogenic retinopathy
was described once in a patient treated with the experimental drug
denileukin diftitox (a fusion protein of portions of diphtheria toxin
and interleukin (IL)-2 that targets IL-2 receptors on malignant cells
and induces apoptosis.93 Optic nerve neuropathy is another condi-
tion that threatens the vision, because progressive optic atrophy is
generally followed by loss of acuity and the visual field. Two types of
involvement can occur: prelaminar (the tumor mass can be seen
along the papilla) and retrolaminar (signs of papillary edema are
evident). Optic nerve infiltration occurs in approximately a fourth of
patients with CLL and with leukemic meningitis, and can be an early
manifestation of CLL or can occur later throughout the dis-
ease.18,94-96 Chemotherapy plus radiotherapy is the mainstay of
reatment, with a good outcome. When facing a patient with a pre-
ious diagnosis of CLL andwho presents with a sudden loss of vision,
full ophthalmologic examination is mandatory followed by neuro-
maging. If a papillar mass or papilledema is present, then the diag-
osis of optic nerve infiltration by CLL should be considered. Be-
ause a lesion biopsy is not always feasible and knowing that
oncurrent meningeal infiltration and optic neuropathy may occur,
mmunophenotyping of CSF lymphocytes is useful in differentiating
eukemic optic nerve infiltration from other causes of optic nerve
amage.
CLL and Progressive Multifocal Leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) refers to a
neurologic disorder characterized by myelin destruction of the CNS
caused by JC virus (JCV), named after the initials of the patient in
whom it was first discovered. The virus is ubiquitous, found in at
least 85% of the general adult population. It remains inactive in
healthy individuals and causes disease only when the immune system
has been severely compromised, such as in people with human im-
munodeficiency virus or AIDS, or hematologic malignancies, and, in
organ transplant recipients who take immunosuppressive drugs to
avoid rejection of the transplanted organ. PML is a progressive dis-
ease because it continues to get worse and often leads to serious brain
damage that is multifocal. However, it is possible for an individual with
PML to have only 1 brain lesion instead of several lesions, which some-
times may cause a problem in the differential diagnosis. The term leu-
koencephalopathy means that the disease mainly affects the white
matter of the brain (more precisely, the axonal myelin of the oligo-
dendrocytes, and it produces cellular intranuclear inclusions), al-
though there are some rare cases in which the graymatter neurons are
also involved. Symptoms include weakness or paralysis, vision loss,
impaired speech, and cognitive deterioration. Focal neurologic signs
include aphasia, hemiparesis, ataxia, cortical blindness, and, less fre-
quently, head tremor. Focal signs tend to be related to posterior brain
(occipital lobes) lesions. Conjugate gaze abnormalities are common,
and this is the initial presentation in 30% of patients. Abnormal-
ities may progress to quadriparesis and coma. Occasionally, neuro-
logic signs are more diffuse rather than focal. PML is diagnosed by
testing for JCV DNA in CSF or in a brain biopsy specimen. PCR of
the CSF has been shown to be highly specific (92%-99%) and sen-
sitive (74%-93%) for the detection of JCV in patients with PML.
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Rodrigo Lopes da SilvaStereotactic brain biopsy is the criterion standard to diagnose PML.
Histology results reveal single or multiple areas of demyelination that
contain JCV-infected oligodendrocytes with enlarged nuclei in the
periphery of the lesions, reactive gliosis with bizarre astrocytes, lipid-
laden macrophages phagocyting myelin, and cellular debris. Al-
though the demonstration of JCV in the brain is helpful, it is not
necessary to make the diagnosis. Patients in whom CSF and brain
PCR for JCV are negative can be diagnosed by immunolabeling of
glial cells by anti-JCV antibody.97 Characteristic evidence of the
amage caused by PML in the brain can also be detected onmagnetic
esonance images, which classically show multifocal nonenhancing
esions without mass effect. Lesions are predominantly located in the
eriventricular and subcortical frontal and parieto-occipital white
atter, followed by a decreasing likelihood in the brainstem, cere-
ellum, thalamus, corpus callosum, and, rarely, the cervical and tho-
acic spinal cord. These lesions are typically asymmetric, diffuse,
ubcortical, and localized to the white matter. Treatment trials with
idofovir, topotecan, and interferon alfa have been inconclusive.98
Other antiviral agents that have been studied as possible treatments
for PML include IL-2, but this research is still preliminary. Cytara-
bine, a chemotherapy drug used to treat certain cancers, has been
prescribed on an experimental basis for a small number of patients
with non-AIDS PML.99 It is reported to have stabilized the neuro-
logic condition of a minority of these patients. There also is evidence
to suggest that the JCV uses serotonin 5HT2A receptors to infect
glial cells. Isolated case reports have demonstrated that serotonergic
receptor antagonists, such as risperidone and mirtazapine, might be
useful in the treatment of PML.100,101 More studies are needed to
onfirm this benefit. Cellular immunity is the mainstay of defense
gainst JCV. CD4 helper T lymphocytes recognize virus particles
nd stimulate CD8 cytotoxic T lymphocytes (CTL). The presence
f JCV-specific CTL is associated with prolonged survival in patients
ith PML. Immune humoral and cellular dysfunctions are inherent
o CLL, and patients more frequently die of infections than the
alignancy itself. Additional immunosuppression caused by CLL
herapy also contributes and acts as a trigger to the worsening of
ell-mediated immunity in CLL. In this context, since the first de-
cription of CLL-associated PML in 1958,102 establishment of more
ntense chemotherapy regimens, including the purine analogue flu-
arabine or even the monoclonal antibody rituximab, contributed to
he increasing amount of PML cases observed in recent years.103,104
A decrease in the CD4 and CD8 lymphocyte subpopulations
counts to levels below 200 cells/L is observed after the initial
3 courses of treatment with fludarabine, and the recovery is slow.105
Cladribine, another purine analogue used in some instances to
treat CLL, also is associated with a great suppression of CD4
counts. These low counts may persist for a median period of time of
40 months after treatment.106 PML in the context of treatment-
aive patients with CLL has lost ground, and, since 1990, 90% of the
ases of PML observed among patients with CLL occurred in those
reated with purine analogues.107-119 In an univariate analysis, 3
ignificant risk factors for developing PML were identified: age55
years, male sex, and CD4 cell count 200 cells/L.117 The exact
ncidence of CLL-related PML is difficult to ascertain because the
iagnosis is based on clinical findings and is not usually done until a
ostmortem examination is performed. Besides, variable disparitiesn case reporting and incomplete reporting and data on the patients
ith purine-associated PML cases, allied to the nature of the studies
one so far, which mainly include case studies and pooled case series
eviews contribute to this issue.118 To illustrate this, the PML inci-
ence varied in 1 series that comprised 962 patients with CLL from
.52%119 to a high value of 5% in 60 patients with CLL treated with
fludarabine.4 In another recently published series, the incidence in
5 patients with CLL and treated with fludarabine or monoclonal
ntibodies was 6.6%.118 Moreover, in another retrospective study,
which included patients with CLL diagnosed between January 2000
and June 2008, it was noted that the incidence rate of PML in the
CLL cohorts, was 11.1 (range, 0.28-61.74) per 100,000 person-
years.120 The median interval from purine analogues to PML was 11
months according to 1 study.117 The median time of survival in
atients with CLL and with PML is 3 months (range, 1-28 months)
ccording to 1 study and 4.3months in another analysis.117,121 Until
fficacious treatment is discovered for the treatment of PML induced
y a JCV opportunistic infection, the prognosis continues to remain
ery poor. As a final reminder, clinicians who deal with patients with
LL should be aware of the potential for PML development, prin-
ipally in those patients previously or currently being treated with
gents that impair T-cell function, such as those used nowadays as
p-front therapy for CLL.
CLL and Second Malignant Neoplasms (Brain Tumors)
Many studies and surveys have established that patients with CLL
are more prone to develop second neoplasms when compared with
the general population. However, the first study to report an associ-
ation between CLL and the risk for developing brain cancer was a
retrospective study that involved 81 patients with CLL, of whom 16
were found to have another malignant neoplasm subsequent to CLL
diagnosis, which translated into a 1.7-fold increased risk for the ap-
pearance of second neoplasms. Among them, brain cancer occurred
unexpectedly at a higher incidence. Four patients with CLL had
multiple cancers, and, curiously, 1 patient had a triple cancer (astro-
cytoma, breast cancer, and melanoma).122 In another, larger study,
hat comprised 9456 patients with CLL, 840 developed second neo-
lasms with an observed-to-expected ratio [O-E]  1.28. Brain tu-
ors were more prevalent, principally in men (O-E  1.98). After
LL diagnosis, the risk of second neoplasms was not affected by the
nitial treatment category and remained constant along the timeline
ccording to that study.123 It should be noted that, in up to a third of
atients with CLL who develop a second malignancy, a spontaneous
emission of CLL precedes the diagnosis of the secondmalignancy by
onths or years. More recently, in a study that quantified the risk of
econd cancers among 16,367 patients with CLL in the population-
ased SEER (Surveillance, Epidemiology and End Results) Program,
he overall O-E ratio was 1.20, with both groups of patients who
eceived treatment (first course) and no treatment at all having the
ame risk. In that report, 22 of 16367 patients with CLL had brain
ancer (16 glioblastomas, 3 meningiomas, 2 astrocytoma, and 1 gli-
ma), and it was reconfirmed that the male sex is at higher risk for
eveloping brain cancer (O/E 1.91).124 Although second neo-
plasms occur with increased frequency in patients with naive or
treated CLL, it is interesting to note that, paradoxically, their fre-
quency and aggressiveness can be higher after treatment with nucle-
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174oside analogue therapy.125 Impaired humoral and cellular immunity
n CLL allied to therapy-related immunosuppressionmay explain, in
art, the added risk of secondary neoplasms and, even more rarely,
he occurrence of multiple tumors. However, to date, there is not any
vidence or strong association that links immunosuppression to the
isk of developing glioblastomas. So, there must be other mecha-
isms yet to be discovered to justify the increased risk for brain cancer
n patients with CLL. In this regard, viral infections are an area to be
xplored. Because CLL is an indolent disease in most of the cases, the
linician must stay alert for the possibility of occurrence of other
ancers, namely brain cancers after a CLL diagnosis, and they should
e treated as they would be in patients without CLL.
CLL and CNS Bleeding
Hemorrhagic complications in CLL are most often related to
thrombocytopenia either due to decreased megakaryopoiesis caused
by diffuse CLL bone marrow infiltration or to increased peripheral
platelet consumption by platelet autoantibodies (immune thrombo-
cytopenia). Therapy-related immune thrombocytopenia also consti-
tutes a rare adverse effect of some agents used to treat CLL, such as
alemtuzumab, and in this context, a fatal CNS hemorrhage was de-
scribed, despite discontinuation of this drug.126 CNS bleeding as a
eurologic complication associated with CLL is generally an ex-
remely unusual event. Solely 2 isolated cases of a subdural hema-
oma were reported to date: 1 in a patient with CLL, which caused
ocal neurologic signs and with a good outcome after local treatment;
nd 1 diagnosed at autopsy.127,128 In 2 larger retrospective studies, 1
that involved 75 patients with CLL, brain hemorrhage constituted 1
of the major causes of death, with an incidence of 7%,129 whereas, in
another, 1 cohort that comprised 962 patients with CLL, only 1
patient (0.1%) presented intracranial hemorrhage.4 Despite the dis-
repancies of these numbers, CNS bleeding during the course of CLL
s a very rare event but still an important occurrence of which to be
ware.
CLL and CNS Infections
A major issue that patients with CLL have to deal with is the
increased frequency and severity of infectious complications,
which are related to the underlying alterations in immune func-
tion, both humoral immunity (hypogammaglobulinemia) and
cellular qualitative and quantitative defects in B cells, T cells, NK
cells, neutrophils, and the monocyte and/or macrophage lineage
that are inherent to the disease process, to its progression, and
further complicated by the immunosuppressive properties of the
drugs used to treat CLL. Opportunistic infections are a serious
cause of morbidity and mortality in patients with CLL. It is esti-
mated that up to 80% of patients with CLL will develop infec-
tious complications at some time in their disease course, with
infections accounting for up to 60% of deaths. It is important to
underscore that patients with CLL undergoing chemotherapy are
not only at risk of acquiring infections but also at risk of reacti-
vation of latent infections. In treatment-naive patients or those
treated with chlorambucil, pulmonary infections are frequently
caused by bacteria such as Streptococcus pneumonia, Staphylococcus
aureus, and Haemophilus influenzae. With the advent of more
otent drugs, such as the purine analogues (eg, fludarabine) and
he monoclonal antibodies rituximab and alemtuzumab, the spec-
Clinical Lymphoma, Myeloma & Leukemia June 2012trum of organisms that cause infections in these patients is chang-
ing from common bacterial organisms to fewer common oppor-
tunistic pathogens, such as Pneumocystis jiroveci, Listeria monocytogenes,
herpes viruses (herpes simplex virus [HSV], [CMV], EBV) and fungus
(Candida, Cryptococcus, Aspergillus).130 With regard to the sites of
infection in patients withCLL, the CNS is no exception. PMLdue to
opportunistic infection by JCV was already mentioned in a previous
section. Here, discussion will focus on CNS infections caused by
other agents. The most common CNS infection in patients with
CLL is herpes zoster meningoencephalitis. In a retrospective study,
69 of 109 patients with CLL had herpes zoster infection,4 which
onstituted the main complication among the spectrum of all possi-
le neurologic complications associated with CLL. Besides menin-
oencephalitis, patients present with trigeminal zoster or dissemi-
ated zoster; the symptoms include headache, altered mental state,
nd lethargy. Antiviral treatment with acyclovir is associated with
ood responses.131 Subacute HSV type 1 encephalitis as an initial
presentation of CLL was reported only in 1 instance. The rarity of
this type of infection in CLL is remarkable because HSV type 1
encephalitis is the most common cause of adult encephalitis world-
wide.132 Toxoplasmosis caused by Toxoplasma gondii is another op-
portunistic infection that occurs de novo or as a reactivation of a
previous latent infection in an immunocompromised host, such as in
the CLL setting.90,133 Cerebral toxoplasmosis presents as multiple
necrotizing lesions, frequently in the deep central nuclei, posterior
fossa, or lobar regions at the gray-white junction. Microglial nodule
inflammation accompanied by extensive necrosis is commonly seen.
Neuroimaging studies usually show ring-enhanced lesions. The dif-
fuse, non-necrotic, “encephalitic” form of cerebral toxoplasmosis,
which was thought to be unique in AIDS-associated immunodefi-
ciency, also was described for the first time in a patient with advanced
disease stage CLL.134 Coexistence of brain toxoplasmosis with other
eurologic infectious agents (JCV; herpes zoster and CMV) also is
ossible and illustrates well the degree of immunosuppression.88,135
CMV infection in CLL mainly affects the retina and was already
discussed. Among the CNS opportunistic fungal infections in pa-
tients with CLL, meningoencephalitis by Cryptococcus neoformans is
one of the most serious. Although being a treatable condition with
antifungals, patients who are fluconazole resistant have been re-
ported, which is unusual among patients without AIDS.136 It often
s difficult to reach a definitive diagnosis of cryptococcal meningitis
n patients who are negative for human immunodeficiency virus,
specially in patients with an immunosuppressed condition, T-cell
uppression may present with less typical clinical manifestations of
eningitis, and a delayed diagnosis is an important issue, with a
eported crude mortality of 19.1%.137 Adverse prognostic factors
that predict treatment failure are steroid treatment, leukocytosis,
mental status, high opening pressure during lumbar puncture, low
CSF glucose level,20 leukocytes/mL3 in CSF, positive CSF smear,
vidence of disseminated disease by positive blood cultures or ele-
ated antigen titers in the blood or CSF, mental changes, age 60
ears, and underlying malignancies.138 Other more uncommon
gents to take into account in a patient with CLL and with suspected
NS infection are Listeria, which can cause a fulminant meningoen-
ephalitis139; pneumococcal meningitis; cerebral Aspergillosis, which
presented in 1 instance as an aspergillus brain emboli4 and also was
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Rodrigo Lopes da Silvadescribed in a relapsed patient with CLL who was being treated with
a combination of alemtuzumab and steroids, and who achieved a
complete recovery after prompt fungal therapy140; and infection by
orrelia burgdorferi,which was diagnosed in a patient with untreated
LL and with a suspected viral encephalitis but whose serologic
nalysis of CSF sample precluded the initial hypothesis, and confir-
ation of Borreliae was done by enzyme-linked immunosorbent
ssay.57
CLL and Therapy-Related Neurologic Disease
Therapeutic advances in CLL, in addition to the benefits in terms
of response rates and better disease control, also has resulted in the
appearance of some adverse effects, for example, neurotoxicity. This
has an important impact on quality of life and may even limit the use
of the treatment. With the increasing use of multiple modality ther-
apy, neurotoxicity can be induced by synergistic or additive effects of
antineoplastic therapy, so early diagnosis is essential because a de-
layed recognition generally has irreversible consequences. Regarding
the agents commonly used to treat CLL, all of them present amore or
less marked profile of neurotoxicity. Chlorambucil, an alkylating
agent used to treat CLL in the prepurine analogue era is still an
option in older patients who have contraindications to the more
recent drugs. This drug has been associated with cases of myoclonus
and seizures, even in therapeutic dosages.141,142 The purine analogue
fludarabine, beyond being associated with an increased risk of JCV-
induced PML, causes mild and reversible neurotoxicity in about
15% of patients with CLL in the conventional dosage.143 Advanced
age (60 years) and higher than the recommended doses are risk
factors for purine analogue–associated neurotoxicity. Fludarabine
presents a dose-relationship neurotoxicity profile. At higher doses
(50 mg/m2/d for 5 days), it causes severe irreversible CNS toxicity
nd death.143,144 Neural alterations, such as diffuse white matter loss
n CNS imaging, are typical, and clinical neurologic complications
nclude blindness and encephalopathy.145 In the context of hemato-
poietic stem cell transplantation, fludarabine-induced toxic leukoen-
cephalopathy affects up to 2.4% of patients and can be subdivided in
3 entities: posterior reversible encephalopathy syndrome, character-
ized by reversible seizures, headache, vision disturbances, and mental
derangements; acute toxic leukoencephalopathy; and other leukoen-
cephalopathies, which are generally fatal due to permanent cognitive
dysfunction.146 Themonoclonal antibody rituximab associated neu-
rotoxicity is very rare and includes occasional cases of PML, posterior
reversible encephalopathy syndrome, and hyperammonemic en-
cephalopathy.147,148 Development of moderate or worse neurotox-
city should result in discontinuation of that drug. Other agents used
s part of the treatment regimen for CLL, such as cyclophosphamide,
endamustine, or oxaliplatin, also were described in anecdotal re-
orts as having potential neurotoxicity. However, no single case was
escribed in the context of CLL management. Notwithstanding the
bsence of reported neurotoxicity with the use of these agents in
LL, the possibility of severe neurologic sequelae related to their use
hould raise the clinician awareness of the possibility of such drug
dverse effects.
Besides neurotoxicity, CNS infection is another collateral effect
ssociated with CLL therapy. PML incidence is higher among pa-
ients with CLL treated with the purine analogue fludarabine. Highnd prolonged corticosteroid use or steroid combination–based
herapies aggravate the immune function and host defense mecha-
isms, predisposing patients to a variety of infections that include
acterial, fungal, viral, and parasitic.149 It was shown that, in patients
with CLL who were receiving fludarabine plus prednisolone, infec-
tions occurred more often than in those not receiving steroid
therapy.150
CLL and Peripheral Nervous
System Neurologic Manifestations
CLL involvement of the peripheral nervous system (PNS) albeit
very rare, can be manifest in a broad myriad of different ways, in-
cluding cranial nerve palsies, acoustic neuropathy, ophthalmoplegia,
femoral neuropathy, and peripheral neuropathy due to leukemic in-
filtrations of peripheral nerve roots and/or plexus and spinal roots,
with or without associated leptomeningeal involvement.151-153 De-
rangements in the immune regulation are frequent in CLL, especially
autoimmune hemolytic anemia, but nonhematologic autoimmune
neuropathies phenomena, such as the chronic inflammatory demy-
elinating polyradiculoneuropathy, necrotizing vasculitis, and Guil-
lain-Barré syndrome (GBS), and other inflammatory neuromuscular
disorders also are associated with CLL and tend to occur even in the
early stages of CLL disease.154-156 Among them, GBS or its variants,
uch as the Miller-Fisher syndrome or acute pandysautonomia, have
een described several times in the context of CLL.157-160 Although
GBS is a postinfectious, immune-mediated disease generally trig-
gered by Campylobacter jejuni infection, it is further known that
herpes zoster infection, which is frequent among patients with CLL,
significantly increases the risk for developing GBS, and this explains,
in part, the many cases of CLL-associated GBS.161 Myasthenia gra-
vis, an autoimmune disease of the neuromuscular junction was de-
scribed over a dozen times concurrently with CLL. It is known that
the incidence of CLL is higher in patients with myasthenia gravis
who have an intact thymus compared with those who have had a
thymectomy. However, the exact relationship between both entities
remains to be elucidated, that is, if both have a common pathogenesis
or their coexistence can be purely coincidental.162 Regarding the
CLL-associated peripheral neuropathies, it is very difficult to guar-
antee with absolute certainty, even with the aid of clinical and histo-
pathologic data, if their natures are exclusively neoplastic, paraneo-
plastic, inflammatory, iatrogenic, or incidental. Most probably, in
some cases, different etiopathogenic mechanisms take part in the
genesis of the neurologic disease.163
CLL and Metabolic
Neurologic Disease
CLL-associated vitamin deficiencies have been reported in some
studies (thiamine, folic acid, cobalamin, tocopherol, and 1,25-dihy-
droxyvitamin D).164-168 The proposed hypothesis for the etiopatho-
genesis of vitamin imbalances found in CLL is related to an increased
nutrient consumption by the tumor cells. In patients withCLL, these
derangements may go unnoticed but can potentially progress to rel-
evant neurologic disease. CLL-associated thiamine (vitamin B1) de-
ficiency manifestations are generally subclinical.164 However, under
precipitating factors, for example, chemotherapy, continuous vita-
min depletion may eventually trigger clinical nervous system mani-
festations (dry beriberi).
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176Disturbances in electrolyte equilibrium are uncommon in CLL
and are related to the disease process itself or to therapeutic interven-
tions. Among the possible ionic imbalances, hypercalcemia and hy-
ponatremia constitute the most important ones, because life-threat-
ening neurologic derangements may develop. High serum calcium
levels in CLL can appear during disease progression (elevation of
white blood counts).169 The mechanisms that underlie hypercalce-
mia in CLL are related to humoral-mediated bone liberation of cal-
cium by the parathyroid hormone due to parathyroid hormone–
related protein produced by the malignant B lymphocytes.170-175
Hypercalcemia-induced neurologic symptoms include alteration of
mental status, lethargy, depression, headache, confusion, and even-
tually coma. Hyponatremia is another condition that, if left un-
treated, is fatal due to manifestations of cerebral edema, including
headache, confusion, epilepsy, and coma. Coexisting hyponatremia
and CLL have been reported in 5 patients, 1 due to iatrogenic causes,
in a patient treated with alternative medicine, and the remaining 3
cases in patients with the syndrome of inappropriate secretion of
antidiuretic hormone secondary to leukemic meningitis infiltration
or pituitary gland invasion.15,33,44,176 Although very rare, CLL-re-
lated electrolyte imbalances should be sought and identified because
prompt treatment avoids evolution to clinical manifestations.
CLL and Paraneoplastic
Neurologic Syndromes
Paraneoplastic neurologic syndromes are a group of rare disorders
that involve any part of the central and peripheral nervous system,
the neuromuscular junction, or muscles, and that affect 1% of
cancer patients. Paraneoplastic neurologic syndromes are mostly en-
countered in small-cell lung cancer followed by ovarian and breast
cancer, thymoma, and, in a minority of cases, lymphomas.177,178 As
general rule, the neurologic manifestations precede the clinical on-
et of cancer and, therefore, can go unnoticed. The recent observa-
ions that paraneoplastic neurologic syndromes are, in many in-
tances, immune-mediated disorders led to the increasing
mportance given to the onconeural antibodies, which recognize an-
igens expressed by the nervous system and by neoplastic cells as a key
eans to diagnose true paraneoplastic neurologic syndromes.179 The
spectrum of entities that encompass the paraneoplastic neurologic
syndromes can be split into 2 groups. First, the “classic syndromes”
are often associated with cancer, whose diagnosis should not delay
the search for an occult neoplasm. These syndromes include enceph-
alomyelitis, limbic encephalitis, subacute cerebellar degeneration,
subacute sensory neuronopathy, Lambert-Eaton myasthenic syn-
drome, and opsoclonus-myoclonus. Second, the remaining other
disorders, GBS, Stiff person syndrome, subacute sensorimotor neu-
ropathy, and so forth, are defined as “nonclassic syndromes.”180 To
date, no association betweenCLL and paraneoplastic neurologic syn-
dromes has been described. However, there is 1 report that describes
a patient with CLL who, after chemotherapy, developed nonhemic
autoimmune complications, which included glomerulonephritis,
paraneoplastic pemphigus, and neurologic symptoms, with image-
documented cerebral lesions suggestive of “nonclassic” paraneoplas-
tic neurologic syndromes. Although this could have been the first
report of a possible paraneoplastic neurologic syndrome associ-
ated with CLL, ultimately it failed to fulfill the diagnostic criteria
Clinical Lymphoma, Myeloma & Leukemia June 2012of paraneoplastic neurologic syndromes because no onconeural
antibodies were detected, and the period of time between CLL
diagnosis and the onset of neurologic symptoms exceeded the
time limit set out in the criteria.181 Other entities, previously
onsidered as paraneoplastic neurologic syndromes but no longer
n the current recommendations, such as cancer-associated reti-
opathy and myasthenia gravis, have been associated with CLL
nd are described elsewhere in this review. However, as men-
ioned before, the “nonclassic“ paraneoplastic neurologic syn-
romes GBS also was described in association with CLL. How-
ver, it was clearly demonstrated that it was not linked to the
ancer but to concurrent CLL-related opportunistic infections or
n incidental finding.
Conclusions
CNS and PNS complications are important issues that clinicians
and hemato-oncologists must bear in mind when dealing with pa-
tients with CLL who present with neurologic symptoms. It is neces-
sary to consider neoplastic parenchymal and/or meningeal infiltra-
tion; secondary brain tumors; opportunistic infections, including
progressive multifocal leukoencephalopathy; CNS hemorrhage; and
peripheral neuropathies in the differential diagnosis in these situa-
tions. Early identification and prompt CNS-directed treatment or
modification of the previous disease management strategy can posi-
tively affect morbidity and quality of life. Notwithstanding, a search
for prognostic factors for the risk of CNS involvement as well as
defining the optimal treatment is needed to achieve a better and
durable response and outcome.
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